Clinical trials: Recurrent Malignant Glioma
Glioblastoma, Gliosarcoma
Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)
Primary objective: To evaluate activity of imatinib mesylate and hydroxyurea among patients with progressive/recurrent grade II low-grade glioma (LGG) as measured by 12-month progression free survival Secondary objectives: To…
- Trial name
- NCT00615927
- Testing
- Imatinib Mesylate & Hydroxyurea
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Duke University
Advanced Solid Tumors, Advanced Recurrent Ovarian Tumors
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
To determine the maximum tolerated dose or optimal biological dose, and the safety profile of MEDI3617 when given as a single-agent or in combination with other chemotherapeutic agents in subjects with advanced solid malignancies…
- Trial name
- NCT01248949
- Testing
- MEDI3617, Bevacizumab, Paclitaxel
- Where
- 10 sites in United States
- Volunteers
- 162 people
- Sponsor
- MedImmune LLC
Glioblastoma Multiforme
Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma
This is a phase II study of the combination of Avastin and metronomic temozolomide in recurrent malignant glioma patients. The primary objective will be to determine the efficacy of Avastin (bevacizumab) and metronomic…
- Trial name
- NCT00501891
- Testing
- Bevacizumab, Metronomic Temozolomide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Duke University
Brain Tumors, Osteoporosis
Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma
RATIONALE: Zoledronate may prevent bone loss in patients with primary malignant glioma. PURPOSE: This phase II trial is studying how well zoledronate works in preventing osteoporosis in patients with primary malignant glioma.
- Conditions
- Brain Tumors, Osteoporosis, Central Nervous System(CNS)Malignancies
- Trial name
- NCT00301873
- Testing
- IV Zometa
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Duke University
Glioblastoma Multiforme, Anaplastic Astrocytoma
Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children
This pilot will study the feasibility and exploratory efficacy of using Cabozantinib for recurrent or refractory central nervous system tumors for which there are no curative options.
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Malignant Brain Tumor, High Grade Glioma
- Trial name
- NCT02885324
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Indiana University
Glioblastoma, Gliosarcoma
Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
Primary objective: To estimate 6-month progression free survival probability of pts w recurrent malignant gliomas treated w erlotinib + bevacizumab.
- Trial name
- NCT00671970
- Testing
- Bevacizumab and Erlotinib
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Duke University
Medulloblastoma, Ependymoma
Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers
Background: More than 130 primary tumors of the central nervous system (CNS) have been identified. Most affect less than 1,000 people in the United States each year.
- Conditions
- Medulloblastoma, Ependymoma, Pineal Region Tumors, Choroid Plexus Tumors
- Trial name
- NCT03173950
- Testing
- Nivolumab, EKG, MRI Brain and/or spine
- Where
- 3 sites in United States
- Volunteers
- 136 people
- Sponsor
- National Cancer Institute (NCI)
High Grade Glioma, BRAF V600E
Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG
The goal of this study is to estimate the efficacy of encorafenib and binimetinib as measured by radiographic response in recurrent high-grade primary brain tumors.
- Conditions
- High Grade Glioma, BRAF V600E, BRAF V600K, Anaplastic Astrocytoma
- Trial name
- BRAF (NCT03973918)
- Testing
- Encorafenib, Binimetinib, Research Bloods
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Brain and Central Nervous System Tumors
Bevacizumab in Treating Patients With Recurrent or Progressive Glioma
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00337207
- Testing
- bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Northwestern University
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide
This phase II trial is studying how well VEGF Trap works in treating patients with recurrent malignant or anaplastic gliomas that did not respond to temozolomide.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00369590
- Testing
- ziv-aflibercept, pharmacological study, laboratory biomarker analysis
- Where
- 7 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
Brain Tumors
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
The purpose of this study is to: Find out how safe and effective (by monitoring the good and/or bad effects) treatment with high dose temozolomide, thiotepa and carboplatin with stem cell rescue followed by 13-cis-retinoic acid…
- Trial name
- NCT00528437
- Testing
- temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid
- Where
- 17 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- NYU Langone Health
Recurrent High-Grade Gliomas, Malignant Gliomas
Bevacizumab for Recurrent Malignant Glioma
Background: Bevacizumab is a genetically engineered antibody that blocks the growth of new blood vessels in tumors. Inhibiting the formation of these blood vessels may slow or stop disease progression by diminishing the supply of…
- Trial name
- NCT00271609
- Testing
- Bevacizumab
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- National Cancer Institute (NCI)
Central Nervous System Neoplasms, Medulloblastoma
A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
This study will assess the efficacy, safety and tolerability of pomalidomide in children and young adults aged 1 to < 21 years with recurrent or progressive primary brain tumors in one of four primary brain tumor types…
- Trial name
- NCT03257631
- Testing
- Pomalidomide
- Where
- 22 sites in United States, France and 3 more
- Volunteers
- 53 people
- Sponsor
- Celgene
Malignant Glioma, Recurrent Brain Neoplasm
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
This phase I trial studies the side effects and best dose of selinexor in treating younger patients with solid tumors or central nervous system (CNS) tumors that have come back (recurrent) or do not respond to treatment…
- Conditions
- Malignant Glioma, Recurrent Brain Neoplasm, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Glioblastoma
- Trial name
- NCT02323880
- Testing
- Pharmacological Study, Selinexor
- Where
- 23 sites in United States
- Volunteers
- 59 people
- Sponsor
- Children's Oncology Group
Adult Glioblastoma, Endometrial Clear Cell Adenocarcinoma
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
This phase I trial studies the side effects and best dose of raptor/rictor-mammalian target of rapamycin (mTOR) (TORC1/2) inhibitor MLN0128 when given in combination with bevacizumab in treating patients with glioblastoma, a type…
- Conditions
- Adult Glioblastoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Ovarian Clear Cell Cystadenocarcinoma
- Trial name
- NCT02142803
- Testing
- Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Glioblastoma Multiforme, Malignant Glioma
Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients
It has been shown that bevacizumab has significant anti-tumor activity in patients with recurrent glioblastoma multiforme. Vorinostat has modest anti-tumor activity against malignant glioma and can enhance the action of both…
- Conditions
- Recurrent Glioblastoma Multiforme, Malignant Glioma, Adult Brain Tumor
- Trial name
- NCT01738646
- Testing
- Vorinostat, Bevacizumab
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Duke University
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
This phase II Pediatric MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma
- Trial name
- NCT03155620
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy
- Where
- 172 sites in United States, Australia and 2 more
- Volunteers
- 1,377 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Glioblastoma, Recurrent Malignant Glioma
Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
This phase I trial studies the side effects and best dose of genetically modified T-cell immunotherapy in treating patients with malignant glioma that has come back (recurrent) or has not responded to therapy (refractory).
- Conditions
- Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma
- Trial name
- NCT02208362
- Testing
- Arm 1: IL13Ra2-specific CAR Tcm cells, Arm 2: IL13Ra2-specific CAR Tcm cells, Arm 3: IL13Ra2-specific CAR Tcm cells
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- City of Hope Medical Center
Glioma
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors
This study will determine whether the drugs tamoxifen and bortezomib can delay tumor growth in patients with recurrent glioma (malignant brain tumor).
- Trial name
- NCT00108069
- Testing
- Tamoxifen citrate, Bortezomib
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
HIGH GRADE GLIOMA
Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab
The Primary Objectives are: To determine the extent by which TH-302 is able to penetrate the blood brain barrier and affect tumor tissue To assess the safety of single dose TH-302 in patients with high grade glioma undergoing…
- Trial name
- NCT01403610
- Testing
- TH-302 preoperative, TH-302 (escalating) with bevacizumab 10mg/kg
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- The University of Texas Health Science Center at San Antonio